VectorBuilder
@vectorbuilder.bsky.social
VectorBuilder is a global leader in gene delivery technologies.
🎉 Annual Survey winners announced Wednesday, February 11 🎉
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
February 6, 2026 at 10:03 AM
🎉 Annual Survey winners announced Wednesday, February 11 🎉
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
Keep an eye out—you might see your name!
Thank you to everyone who shared feedback and helped shape what’s next for VectorBuilder.
🧬 How do diseases initiate at the genetic level?
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
February 5, 2026 at 4:11 PM
🧬 How do diseases initiate at the genetic level?
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Our next Gene Delivery Seminar highlights how early genetic events are studied in vivo, with relevance to cancer biology and beyond.
Sign up now: us06web.zoom.us/webinar/regi...
Last week, we highlighted how IVT RNA design optimization improves R&D performance. This week, we’re focusing on LNP-RNA delivery and how formulation and antibody conjugation enhance outcomes.
More next week on clinical applications!
More next week on clinical applications!
February 5, 2026 at 4:09 PM
Last week, we highlighted how IVT RNA design optimization improves R&D performance. This week, we’re focusing on LNP-RNA delivery and how formulation and antibody conjugation enhance outcomes.
More next week on clinical applications!
More next week on clinical applications!
On World Cancer Day, we honor patients and their families while recognizing the significant advances in cancer research and the work that remains to be done. That’s why we support scientists working to turn discoveries into real impact for all patients.
February 4, 2026 at 3:46 PM
On World Cancer Day, we honor patients and their families while recognizing the significant advances in cancer research and the work that remains to be done. That’s why we support scientists working to turn discoveries into real impact for all patients.
Congratulations to Ilia Kurochkin and the @cellreprolab.bsky.social on their publication introducing REPROcode, a platform for combinatorial transcription factor screening that enables controlled immune cell reprogramming toward distinct lineages.
We’re excited to share that our recent paper, “A combinatorial transcription factor screening platform for immune cell reprogramming”, has been selected for the cover of the January issue of Cell Systems!✨
February 2, 2026 at 2:58 PM
Congratulations to Ilia Kurochkin and the @cellreprolab.bsky.social on their publication introducing REPROcode, a platform for combinatorial transcription factor screening that enables controlled immune cell reprogramming toward distinct lineages.
This is your final opportunity to let us know what’s working and where we can improve; our annual survey closes on January 31!
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
January 30, 2026 at 4:36 PM
This is your final opportunity to let us know what’s working and where we can improve; our annual survey closes on January 31!
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
Your feedback directly informs the development of future VectorBuilder tools and improvements. Complete the survey for a chance to win up to $1,000 in store credit.
🧬 Did you know acute lymphoblastic leukemia is the most common childhood cancer? But how does it begin?
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
January 29, 2026 at 3:06 PM
🧬 Did you know acute lymphoblastic leukemia is the most common childhood cancer? But how does it begin?
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
Join our next Gene Delivery Seminar with @jamesrallen.bsky.social, @hhmi-science.bsky.social Hanna Gray Fellow and incoming faculty at @mayoclinic.org, on February 19.
CRISPR therapies are no longer a pipe dream. As genome editing moves into the clinic, delivery is now the real challenge.
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
EBR Winter 2026
Weclome to EBR Winter 2026! Featuring articles on CRISPR Screening, Vaccines, Biosimilars and Biologics. Richter BioLogics showcases its CDMO services in its Supplement!
www.calameo.com
January 28, 2026 at 4:58 PM
CRISPR therapies are no longer a pipe dream. As genome editing moves into the clinic, delivery is now the real challenge.
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
In her latest article, Dr. Connie Rich explores how delivery design shapes which CRISPR therapies reach patients safely and at scale.
Read here: www.calameo.com/read/0061133...
Have you met VectorBuilder’s end-to-end IVT RNA platform? This week, we’re highlighting how our IVT RNA design optimization strategies support performance and consistency throughout the R&D process.
Stay tuned next week as we explore LNP delivery!
Stay tuned next week as we explore LNP delivery!
January 27, 2026 at 5:46 PM
Have you met VectorBuilder’s end-to-end IVT RNA platform? This week, we’re highlighting how our IVT RNA design optimization strategies support performance and consistency throughout the R&D process.
Stay tuned next week as we explore LNP delivery!
Stay tuned next week as we explore LNP delivery!
A reminder that our Annual User Survey is still open, but not for long. Your feedback plays a key role in shaping future VectorBuilder improvements.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
January 23, 2026 at 3:54 PM
A reminder that our Annual User Survey is still open, but not for long. Your feedback plays a key role in shaping future VectorBuilder improvements.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
Take a few minutes to share your experience and enter to win store credit prizes up to $1,000.
Our first Gene Delivery Seminar of the year kicks off TODAY! Dr. @cristina-mtz-glz.bsky.social will share practical insights on choosing tissue-clearing approaches and utilizing advanced imaging to visualize intact samples in 3D.
Interested in tissue-clearing techniques to study intact samples in 3D? Catch Dr. Cristina Martinez Gonzalez's talk (@cristina-mtz-glz.bsky.social) as she introduces novel tissue-clearing strategies & key considerations for selecting the right protocol for different samples & research objectives.
January 22, 2026 at 2:30 PM
Our first Gene Delivery Seminar of the year kicks off TODAY! Dr. @cristina-mtz-glz.bsky.social will share practical insights on choosing tissue-clearing approaches and utilizing advanced imaging to visualize intact samples in 3D.
You spoke. We listened. New Updates. 🧬
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
January 21, 2026 at 5:51 PM
You spoke. We listened. New Updates. 🧬
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
Since launching in 2024, VectorBee has continued to expand its tools for sequence analysis, vector design, and molecular cloning. If you haven’t used our FREE software yet, check out why scientists are buzzing about it: www.vectorbee.com/en/ 🐝
Meet Ahlem Zaghmi!
From biology to PEG chemistry, Ahlem’s favorite project explored how PEG-grafted enzymes influence therapeutic potential in ischemia—challenging, humbling, and deeply rewarding.
🧬 Open Lab Hours | Free 1:1 PhD sessions
📅 Feb 5 & 10: calendly.com/ahlemzaghmi-...
From biology to PEG chemistry, Ahlem’s favorite project explored how PEG-grafted enzymes influence therapeutic potential in ischemia—challenging, humbling, and deeply rewarding.
🧬 Open Lab Hours | Free 1:1 PhD sessions
📅 Feb 5 & 10: calendly.com/ahlemzaghmi-...
January 20, 2026 at 11:45 AM
Meet Ahlem Zaghmi!
From biology to PEG chemistry, Ahlem’s favorite project explored how PEG-grafted enzymes influence therapeutic potential in ischemia—challenging, humbling, and deeply rewarding.
🧬 Open Lab Hours | Free 1:1 PhD sessions
📅 Feb 5 & 10: calendly.com/ahlemzaghmi-...
From biology to PEG chemistry, Ahlem’s favorite project explored how PEG-grafted enzymes influence therapeutic potential in ischemia—challenging, humbling, and deeply rewarding.
🧬 Open Lab Hours | Free 1:1 PhD sessions
📅 Feb 5 & 10: calendly.com/ahlemzaghmi-...
If you haven’t had a chance yet, there’s still time to share your feedback and help shape the next wave of VectorBuilder tools and updates. Complete the survey by January 31 to enter for a chance to win up to $1,000 in store credit.
docs.google.com/forms/d/e/1F...
docs.google.com/forms/d/e/1F...
January 15, 2026 at 8:30 PM
If you haven’t had a chance yet, there’s still time to share your feedback and help shape the next wave of VectorBuilder tools and updates. Complete the survey by January 31 to enter for a chance to win up to $1,000 in store credit.
docs.google.com/forms/d/e/1F...
docs.google.com/forms/d/e/1F...
Reminder! Don’t miss our seminar with Dr. Cristina Martinez Gonzalez as she introduces novel tissue-clearing strategies and key considerations for selecting the right protocol for different samples and research objectives.
Register here! us06web.zoom.us/webinar/regi...
Register here! us06web.zoom.us/webinar/regi...
Interested in tissue-clearing techniques to study intact samples in 3D? Catch Dr. Cristina Martinez Gonzalez's talk (@cristina-mtz-glz.bsky.social) as she introduces novel tissue-clearing strategies & key considerations for selecting the right protocol for different samples & research objectives.
January 14, 2026 at 3:50 PM
Reminder! Don’t miss our seminar with Dr. Cristina Martinez Gonzalez as she introduces novel tissue-clearing strategies and key considerations for selecting the right protocol for different samples and research objectives.
Register here! us06web.zoom.us/webinar/regi...
Register here! us06web.zoom.us/webinar/regi...
New study from the Torkamaneh lab @ulaval.ca uses CRISPR knockouts to show how nitrogen fixation & root development are genetically linked in soybean.
CRISPR‐induced knockouts reveal a dual role for the soybean NFR5α gene in symbiotic nitrogen fixation and root hair development
Nitrogen fixation in soybeans, facilitated by symbiotic interactions with rhizobia, is a cornerstone of sustainable agriculture, reducing reliance on synthetic fertilizers. However, the efficiency of...
acsess.onlinelibrary.wiley.com
January 13, 2026 at 3:06 PM
New study from the Torkamaneh lab @ulaval.ca uses CRISPR knockouts to show how nitrogen fixation & root development are genetically linked in soybean.
Interested in tissue-clearing techniques to study intact samples in 3D? Catch Dr. Cristina Martinez Gonzalez's talk (@cristina-mtz-glz.bsky.social) as she introduces novel tissue-clearing strategies & key considerations for selecting the right protocol for different samples & research objectives.
January 9, 2026 at 4:45 PM
Interested in tissue-clearing techniques to study intact samples in 3D? Catch Dr. Cristina Martinez Gonzalez's talk (@cristina-mtz-glz.bsky.social) as she introduces novel tissue-clearing strategies & key considerations for selecting the right protocol for different samples & research objectives.
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
January 8, 2026 at 5:11 PM
📣 Share Your Thoughts and Boost Your Research!
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
Our Annual User Survey is now live, and we’d love to hear from you. Your feedback directly helps us improve the tools, services, and support that power your research, including VectorBee upgrades.
In a new Forbes commentary, our COO, Kristofer Mussar, reflects on what customer support looks like in the age of AI and why automation alone isn’t enough.
Read the full piece to learn how balancing technology and humanity can build real trust: www.forbes.com/councils/for...
Read the full piece to learn how balancing technology and humanity can build real trust: www.forbes.com/councils/for...
www.forbes.com
January 7, 2026 at 4:17 PM
In a new Forbes commentary, our COO, Kristofer Mussar, reflects on what customer support looks like in the age of AI and why automation alone isn’t enough.
Read the full piece to learn how balancing technology and humanity can build real trust: www.forbes.com/councils/for...
Read the full piece to learn how balancing technology and humanity can build real trust: www.forbes.com/councils/for...
VectorBuilder has partnered with UK-based Ikarovec Ltd in an exclusive collaboration to advance a promising one-time dual pathway gene therapy for intermediate age-related macular degeneration, a condition with no currently approved treatment options.
January 6, 2026 at 3:45 PM
VectorBuilder has partnered with UK-based Ikarovec Ltd in an exclusive collaboration to advance a promising one-time dual pathway gene therapy for intermediate age-related macular degeneration, a condition with no currently approved treatment options.
Lights are back on, lab benches are ready, & science is officially back in motion. We hope you had time to rest, reset, & maybe even let a few ideas incubate over the break. We’re ready to support your next experiments & discoveries. Here’s to fresh hypotheses & meaningful results in the year ahead!
January 5, 2026 at 6:49 PM
Lights are back on, lab benches are ready, & science is officially back in motion. We hope you had time to rest, reset, & maybe even let a few ideas incubate over the break. We’re ready to support your next experiments & discoveries. Here’s to fresh hypotheses & meaningful results in the year ahead!
In 2025, VectorBuilder went worldwide 🌍🧬
From lab benches to conference halls across the globe, our team connected with researchers sharing ideas, sparking collaborations, and accelerating discovery. Different cities, different time zones, one mission: pushing science forward, wherever it happens.
From lab benches to conference halls across the globe, our team connected with researchers sharing ideas, sparking collaborations, and accelerating discovery. Different cities, different time zones, one mission: pushing science forward, wherever it happens.
December 31, 2025 at 8:52 PM
In 2025, VectorBuilder went worldwide 🌍🧬
From lab benches to conference halls across the globe, our team connected with researchers sharing ideas, sparking collaborations, and accelerating discovery. Different cities, different time zones, one mission: pushing science forward, wherever it happens.
From lab benches to conference halls across the globe, our team connected with researchers sharing ideas, sparking collaborations, and accelerating discovery. Different cities, different time zones, one mission: pushing science forward, wherever it happens.
In 2025, VectorBuilder’s Gene Delivery Seminar Series brought together expert insights, emerging technologies, and practical solutions from across the field. Thanks to our speakers and community for joining us. More to come in 2026!
December 30, 2025 at 5:42 PM
In 2025, VectorBuilder’s Gene Delivery Seminar Series brought together expert insights, emerging technologies, and practical solutions from across the field. Thanks to our speakers and community for joining us. More to come in 2026!
As the year winds down and experiments pause, we’re grateful for the scientists, collaborators, and innovators who made 2025 a great year. Thank you for building the future of science!
December 23, 2025 at 5:09 PM
As the year winds down and experiments pause, we’re grateful for the scientists, collaborators, and innovators who made 2025 a great year. Thank you for building the future of science!
Season’s Greetings from the VectorBuilder team! 🎄
Our holiday party was proof that great science comes with even better people. Fun conversations, lots of laughs, and some of the people who make it all happen ✨
Our holiday party was proof that great science comes with even better people. Fun conversations, lots of laughs, and some of the people who make it all happen ✨
December 22, 2025 at 7:05 PM
Season’s Greetings from the VectorBuilder team! 🎄
Our holiday party was proof that great science comes with even better people. Fun conversations, lots of laughs, and some of the people who make it all happen ✨
Our holiday party was proof that great science comes with even better people. Fun conversations, lots of laughs, and some of the people who make it all happen ✨